NR4A1 and inflammatory breast carcinoma: Our objective was to assess the progression-free survival (PFS) of metastatic hormone receptor-positive HER2-negative/low (HR+HER2−) IBC patients treated with CDK4/6 inhibitors (CDKIs) and hormonal therapy (HT).